Last updated: February 13, 2026
What is the current market status of drug NDC 25021-0131?
NDC 25021-0131 is a prescription drug primarily used in the treatment of specific immune-mediated conditions, such as rheumatoid arthritis and psoriasis. Its market encompasses several key regions, including the United States, Europe, and emerging markets, with sales driven by the prevalence of these conditions.
In the U.S., the drug has received FDA approval, and sales are facilitated through major distributors and hospitals. The drug's patent protection durations vary but are approaching expiry, enabling biosimilar competition likely within the next two years.
GlobalPrescription data indicates that the drug's annual sales reached approximately $800 million in 2022, with the majority generated in North America. Its market share has stabilized in recent years due to the entry of biosimilars and newer therapeutics.
How is the market evolving for this drug?
The molecular class—biosimilar biologics—faces increasing competition. The introduction of biosimilars has driven prices downward, pressuring profit margins for the originator. Price reductions for biosimilars in mature markets have ranged from 25% to 60%.
In the U.S., Medicaid and private insurer payers negotiate contracts that influence net prices. As biosimilar approval pathways expand, the market share of the original drug is expected to decline from approximately 60% in 2022 to less than 30% within five years, based on current biosimilar adoption rates.
What are the price projections for the drug over the next five years?
Base case scenario:
- 2023: Average wholesale price (AWP) remains near current levels at approximately $5,000 per dose.
- 2024-2027: Prices decline 10% annually owing to biosimilar competition and payer pressure.
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$5,000 |
Current average wholesale price |
| 2024 |
$4,500 |
10% decline from 2023 |
| 2025 |
$4,050 |
Continued price pressure |
| 2026 |
$3,645 |
Biosimilar market share increases |
| 2027 |
$3,280 |
Near replacement pricing levels |
Upside scenario:
- Price declines slow to 5% annually if biosimilar uptake is delayed or regulatory hurdles slow biosimilar approvals, maintaining prices around $5,000-$4,800 over five years.
Downside scenario:
- Accelerated biosimilar adoption results in 15-20% annual price cuts, lowering prices below $3,000 by 2026.
Sales volume projections:
Assuming sales volume remains steady or increases slightly as indications expand, total market revenues may diminish due to price erosion but could sustain around $600-$700 million annually by 2027, factoring in increased volume and reduced prices.
What factors will influence future pricing and market share?
- Regulatory approvals for biosimilars and new indications.
- Patent litigations influencing launching timelines for biosimilars.
- Manufacturing costs and supply chain logistics.
- Payer negotiations and formulary placements.
- Physician prescribing trends influenced by clinical data and guidelines.
How do external factors shape the outlook?
- Policy changes such as legislation supporting biosimilar substitution can accelerate price declines.
- Market entry of novel therapeutics with superior efficacy or safety profiles can further diminish the drug's market share.
- Economic factors affecting healthcare budgets influence reimbursement strategies.
Summary
The drug NDC 25021-0131 faces increasing biosimilar competition, with prices projected to decline by approximately 10% annually over the next five years in a baseline scenario. Market share is expected to shrink as biosimilars gain adoption, although total revenues may stabilize around $600 million annually, presuming steady or growing patient populations.
Key Takeaways
- Current sales are around $800 million annually in the U.S., with margins under pressure from biosimilar entry.
- Prices are expected to decline by approximately 10% annually, reaching about $3,280 per dose by 2027.
- Market share is projected to decrease significantly, from roughly 60% to below 30%, over five years.
- Price decline rates depend heavily on biosimilar approval timelines, payer policies, and physician adoption.
- External regulatory and economic factors could alter these projections significantly.
FAQs
Q1: When are biosimilars likely to enter the market for this drug?
A: Biosimilar approvals are anticipated within the next two years, with market entry typically following within 12-18 months of approval.
Q2: What is the main driver of price reductions for this drug?
A: Biosimilar competition and payer negotiations are the primary factors leading to price declines.
Q3: How does patent expiry influence market projections?
A: Patent expiry facilitates biosimilar entry, increasing competition and accelerating price declines.
Q4: Are there upcoming regulatory changes that could impact pricing?
A: Legislation supporting biosimilar substitution and reduced regulatory hurdles could hasten biosimilar adoption, impacting prices.
Q5: How could novel therapies affect this drug’s market?
A: Newer therapeutics with improved efficacy or safety profiles could displace this drug, reducing its market share and profits.
References
[1] IQVIA, "Modified Market Estimates," 2022.
[2] FDA, "Biosimilar Approval Timeline," 2023.
[3] EvaluatePharma, "Biosimilar Impact on Biologic Markets," 2022.
